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Association between C reactive protein and coronary heart
disease: mendelian randomisation analysis based on
individual participant data
C Reactive Protein Coronary Heart Disease Genetics Collaboration (CCGC)
ABSTRACT
Objective To use genetic variants as unconfounded
proxies of C reactive protein concentration to study its
causal role in coronary heart disease.
Design Mendelian randomisation meta-analysis of
individual participant data from 47 epidemiological
studies in 15 countries.
Participants 194418 participants, including 46557
patients with prevalent or incident coronary heart
disease. Information was available on four CRP gene
tagging single nucleotide polymorphisms (rs3093077,
rs1205, rs1130864, rs1800947), concentration of C
reactive protein, and levels of other risk factors.
Main outcome measures Risk ratios for coronary heart
disease associated with genetically raised C reactive
protein versus risk ratios with equivalent differences in C
reactive protein concentration itself, adjusted for
conventional risk factors and variability in risk factor
levels within individuals.
Results CRP variants were each associated with up to
30% per allele difference in concentration of C reactive
protein (P<10
−34) and were unrelated to other risk factors.
Risk ratios for coronary heart disease per additional copy
of an alleleassociatedwithraisedC reactiveproteinwere
0.93 (95% confidence interval 0.87 to 1.00) for
rs3093077; 1.00 (0.98 to 1.02) for rs1205; 0.98 (0.96 to
1.00) for rs1130864; and 0.99 (0.94 to 1.03) for
rs1800947. In a combined analysis, the risk ratio for
coronary heart disease was 1.00 (0.90 to 1.13) per 1 SD
higher genetically raised natural log (ln) concentration of
C reactive protein. The genetic findings were discordant
with the risk ratio observed for coronary heart disease of
1.33 (1.23 to 1.43) per 1 SD higher circulating ln
concentration of C reactive protein in prospective studies
(P=0.001 for difference).
Conclusion Human genetic data indicate that C reactive
protein concentration itself is unlikely to be even a
modest causal factor in coronary heart disease.
INTRODUCTION
Persistent inflammation has been implicated in the
pathogenesis of coronary heart disease, but causality
has not been establishedfor any specific inflammatory
mediator.
1 C reactive protein, an acute phase protein
produced by the liver, is the most extensively studied
systemic marker of inflammation.
2 Observational epi-
demiological studies have shown that C reactive pro-
tein concentration is log linearly related to risk of
subsequent coronary heart disease, though this asso-
ciationdependsconsiderablyonlevelsofconventional
risk factors.
3 C reactive protein binds to low density
lipoproteins
4 and is present in atherosclerotic
plaques.
5 There is, therefore, interest in whether long
termaverage(“usual”)concentrationofCreactivepro-
tein is itself causally relevant to coronary heart
disease.
67 Randomised trials of interventions specific
to C reactive protein, however, have not yet been
done in relation to vascular disease outcomes.
In the absence of such trials, focused genetic studies
can be used to help judge causality. This approach is
known as “mendelian randomisation” because it is
basedonMendel’ssecondlaw,whichstatesthatalleles
of different genes assort independently of one another
during gamete formation. Consequently, mendelian
randomisation analyses are based on Mendel’s obser-
vation that inheritance of one trait should be indepen-
dent of inheritance of other traits.
8 For the causal
assessment of C reactive protein, a mendelian rando-
misation analysis should reduce confounding, pro-
vided the genetic variants used as proxies for
concentration of C reactive protein are unrelated to
conventional vascular risk factors and other disease
markers. Such studies should also avoid distortions
caused by factors occurring later in life (such as the
onset of disease) because genetic variants are fixed at
conception.
8 Hence, mendelian randomisation ana-
lyses should confer certain design advantages akin to
those in randomised trials. When applied to other risk
factors in coronary heart disease, this approach has
previously confirmed the causal relevance of low den-
sity lipoprotein cholesterol,
9 increased the likelihood
of causality for Lp(a) lipoprotein,
10 and reduced the
likelihood of causality for fibrinogen.
11
Findings from previous human genetic studies have
reducedthelikelihoodofamajorcausalroleforCreac-
tive protein concentration in coronary heart
disease.
12-18 As most known genetic variants related to
C reactive protein account for a relatively small por-
tion of the variability in its concentration, however,
even larger and more detailed analyses are needed to
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Age at survey (years)
BMI (kg/m2)
Systolic BP (mm Hg)
Diastolic BP (mm Hg)
Total cholesterol (mmol/L)
Non-HDL cholesterol (mmol/L)
HDL cholesterol (mmol/L)
Ln triglycerides (mmol/L)
LDL cholesterol (mmol/L)
Apolipoprotein A I (g/L)
Apolipoprotein B (g/L)
Albumin (g/L)
Lp(a) lipoprotein (mg/dL)
Ln interleukin 6 (ng/L)
Fibrinogen (µmol/L)
Ln leucocyte count (×109/L)
Glucose (mmol/L)
Smoking amount (pack years)
Weight (kg)
Height (cm)
Waist:hip ratio
0.207 (0.174 to 0.239)
-0.002 (-0.024 to 0.019)
0.011 (-0.012 to 0.034)
0.024 (0.001 to 0.047)
0.009 (-0.015 to 0.032)
-0.001 (-0.026 to 0.023)
0.004 (-0.019 to 0.028)
-0.011 (-0.040 to 0.017)
0.01 (-0.014 to 0.033)
0.005 (-0.019 to 0.029)
0.012 (-0.029 to 0.053)
0.013 (-0.020 to 0.046)
-0.097 (-0.437 to 0.242)
-0.025 (-0.079 to 0.029)
0.006 (-0.045 to 0.056)
0.014 (-0.013 to 0.041)
-0.078 (-0.246 to 0.089)
-0.014 (-0.051 to 0.024)
-0.151 (-0.350 to 0.048)
0.015 (-0.009 to 0.038)
0.011 (-0.017 to 0.040)
0.001 (0.025 to 0.025)
15/70 117
18/81 648
16/73 663
16/74 309
16/74 292
16/72 938
16/70 969
16/70 971
16/70 476
16/68 247
8/58 678
8/58 841
1/2436
3/16 577
6/13 274
13/64 190
2/2938
12/60 961
2/926
14/68 760
14/70 385
8/62 358
-0.3-0.2-0.1 0 0.1 0.2 0.3
Variable SD (95% CI) change
in biomarker per
allele change in SNP
SD (95% CI) change
in biomarker per
allele change in SNP
SD (95% CI) change
in biomarker per
allele change in SNP
No of studies/
participants
5.44x10
-35
0.83
0.34
0.04
0.46
0.91
0.71
0.44
0.42
0.69
0.57
0.45
0.57
0.37
0.83
0.30
0.36
0.48
0.14
0.21
0.44
0.97
-0.3-0.2-0.1 0 0.1 0.2 0.3
P value
rs3093077 (frequency of risk allele: G = 0.06)
0.169 (0.153 to 0.185)
-0.003 (-0.011 to 0.005)
-0.003 (-0.013 to 0.008)
0 (-0.009 to 0.009)
0.006 (-0.004 to 0.017)
-0.001 (-0.010 to 0.007)
-0.004 (-0.013 to 0.005)
0.005 (-0.004 to 0.014)
0.002 (-0.010 to 0.013)
-0.004 (-0.013 to 0.005)
0.007 (-0.004 to 0.018)
-0.001 (-0.011 to 0.010)
0.007 (-0.015 to 0.029)
-0.001 (-0.019 to 0.017)
-0.002 (-0.024 to 0.021)
-0.007 (-0.019 to 0.005)
-0.012 (-0.034 to 0.010)
0.008 (-0.004 to 0.021)
-0.021 (-0.055 to 0.012)
0.006 (-0.007 to 0.020)
0.013 (0.004 to 0.022)
0.009 (-0.003 to 0.020)
30/105 476
37/129 717
33/116 191
31/116 464
31/116 439
33/111 422
33/109 362
33/109 404
32/103 906
32/101 308
14/74 525
16/76250
10/21 480
13/26 953
13/21 810
23/81193
9/18 332
23/83 707
9/7534
29/106 574
29/108 939
20/91 199
No of studies/
participants
1.00x10
-40
0.49
0.64
0.98
0.22
0.75
0.40
0.32
0.78
0.39
0.20
0.90
0.51
0.93
0.87
0.22
0.30
0.20
0.21
0.36
0.003
0.15
P value
rs1205 (frequency of risk allele: C = 0.67)
Ln C reactive protein (mg/L)
Age at survey (years)
BMI (kg/m2)
Systolic BP (mm Hg)
Diastolic BP (mm Hg)
Total cholesterol (mmol/L)
Non-HDL cholesterol (mmol/L)
HDL cholesterol (mmol/L)
Ln triglycerides (mmol/L)
LDL cholesterol (mmol/L)
Apolipoprotein A I (g/L)
Apolipoprotein B (g/L)
Albumin (g/L)
Lp(a) lipoprotein (mg/dL)
Ln interleukin 6 (ng/L)
Fibrinogen (µmol/L)
Ln leucocyte count (×109/L)
Glucose (mmol/L)
Smoking amount (pack years)
Weight (kg)
Height (cm)
Waist:hip ratio
0.127 (0.113 to 0.141)
0.004 (-0.005 to 0.013)
0.007 (-0.004 to 0.017)
0 (-0.009 to 0.009)
0.005 (-0.004 to 0.014)
-0.007 (-0.016 to 0.002)
-0.007 (-0.016 to 0.002)
0 (-0.009 to 0.009)
-0.003 (-0.013 to 0.007)
-0.010 (-0.020 to 0)
-0.007 (-0.018 to 0.004)
-0.008 (-0.019 to 0.003)
0 (-0.023 to 0.023)
-0.004 (-0.024 to 0.015)
-0.007 (-0.029 to 0.016)
0 (-0.010 to 0.011)
-0.008 (-0.032 to 0.016)
0.006 (-0.005 to 0.017)
-0.022 (-0.057 to 0.012)
0.007 (-0.004 to 0.019)
0.005 (-0.006 to 0.017)
0.015 (-0.009 to 0.038)
30/98 411
35/118 917
32/109 149
31/109 799
31/109 780
32/104 375
31/101 822
31/101 845
31/96 995
30/93 902
14/70 707
16/72 548
8/17 970
11/23 485
12/17 694
24/79 166
8/15 731
22/80 236
10/7675
28/99 410
28/101 720
18/86 541
-0.3-0.2-0.1 0 0.1 0.2 0.3
Variable SD (95% CI) change
in biomarker per
allele change in SNP
SD (95% CI) change
in biomarker per
allele change in SNP
SD (95% CI) change
in biomarker per
allele change in SNP
SD (95% CI) change
in biomarker per
allele change in SNP
SD (95% CI) change
in biomarker per
allele change in SNP
No of studies/
participants
1.00x10
-40
0.37
0.23
0.97
0.30
0.14
0.15
0.99
0.55
0.05
0.22
0.16
0.99
0.66
0.57
0.93
0.53
0.26
0.21
0.21
0.36
0.22
-0.3-0.2-0.1 0 0.1 0.2 0.3
P value
rs1130864 (frequency of risk allele: T = 0.30)
0.232 (0.202 to 0.261)
-0.019 (-0.045 to 0.008)
-0.015 (-0.042 to 0.012)
0 (-0.032 to 0.031)
0.002 (-0.025 to 0.028)
0.013 (-0.023 to 0.049)
0 (-0.043 to 0.043)
0.024 (-0.005 to 0.053)
-0.014 (-0.057 to 0.029)
0.009 (-0.029 to 0.047)
-0.003 (-0.045 to 0.039)
0.010 (-0.034 to 0.054)
0.003 (-0.040 to 0.046)
-0.050 (-0.109 to 0.010)
-0.002 (-0.050 to 0.046)
0.001 (-0.042 to 0.044)
0.001 (-0.054 to 0.056)
0.002 (-0.034 to 0.038)
-0.036 (-0.113 to 0.041)
-0.018 (-0.052 to 0.016)
-0.002 (-0.030 to 0.026)
0.003 (-0.034 to 0.039)
19/38 573
25/58 385
22/47 509
20/48 515
20/48 502
22/42 737
22/41 504
22/41 545
22/42 262
22/40 806
9/19 703
11/21 272
9/18 078
9/10 702
8/13 970
12/17 892
6/10 550
15/25 563
6/6477
20/42 650
20/44 760
11/26 347
No of studies/
participants
1.00x10
-40
0.17
0.28
0.98
0.90
0.49
0.99
0.10
0.52
0.64
0.88
0.65
0.89
0.10
0.93
0.96
0.97
0.92
0.36
0.30
0.88
0.89
P value
rs1800947 (frequency of risk allele: G = 0.94)
Fig 1 |Associations of four principal single nucleotide polymorphisms (SNP) related to C reactive protein with various characteristics in individuals free from
known coronary heart disease at time of measurement. Estimates presented are based on random effects meta-analysis of study specific associations ofe a c h
SNP with panel of risk factors, adjusted, where appropriate, for ethnicity. Per allele model corresponds to association per addition of risk allele for each SNP
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role. We report such an analysis based on individual
data from 194418 participants in 47 epidemiological
studies.Westudiedthesegeneticvariantsinrelationto
C reactive protein concentration, other risk factors,
and risk of coronary heart disease.
METHODS
Design and rationale
The study had five inter-related components. Firstly,
we selected, a priori, a panel of four single nucleotide
polymorphismsthatexplain98%ofthevariationinthe
CRP gene in populations of European descent. These
variantshavebeenshowntoinfluenceconcentrationof
C reactive protein without affecting its protein
sequence.
19 Secondly, we studied whether these poly-
morphisms are likely to be exclusively associated with
Creactiveproteinconcentrationbyevaluatingthemin
relation to a range of other risk factors. Thirdly, we
calculated risk ratios for coronary heart disease with
genetically raised concentration using information on
these CRP variants. Fourthly, we calculated risk ratios
for coronary heart disease with circulating C reactive
protein concentration after adjustment for conven-
tional risk factors and variability in risk factors within
individuals.Fifthly,wecomparedriskratiosforcoron-
ary heart disease with genetically raised concentration
of C reactive protein versus risk ratios seen with
equivalent differences in circulating concentrations.
Genetic variants
We used detailed information about the composition
of the CRP gene to select a parsimonious set of “tag-
ging” single nucleotide polymorphisms (rs3093077,
rs1205, rs1130864, and rs1800947) that fully covers
the common variations of this gene in populations of
Europeandescent(thatis,minorallelefrequency≥0.05
and an r
2 threshold of ≥0.8).
1920 Data available on 36
further single nucleotide polymorphisms enabled use
ofproxyvariantswhenprincipalpolymorphismswere
not measured. To enhance power, we also studied
combinations of alleles inherited together, or “haplo-
types” (see table A in appendix 1 on bmj.com).
Contributing studies
Details of the C Reactive Protein Coronary Heart Dis-
ease Genetics Collaboration (CCGC) have been
described previously.
20 Tables B-E in appendix 1 on
bmj.com provides details of contributing studies, and
appendix 2 lists study acronyms. Studies were identi-
fied through registry approaches and systematic
searches of the literature (see fig A in appendix 3, and
appendix 4 on bmj.com). Individual data were sup-
plied on 194418 participants, including 46557 with
incident or prevalent coronary heart disease, in 47 stu-
dies. Studies used different genotyping platforms: 23
used TaqMan assays,three used KASPAR technology
(KBioscience), three used restriction fragment length
polymorphism, 10 used the ITMAT-Broad-CARe
50K SNP array, and eight used other multiplex meth-
ods. Thirty five studies measured C reactive protein
with high sensitivity assays, directly or indirectly stan-
dardised on the International Reference Standard for
C reactive protein immunoassay (WHO 85/506). The
outcome was defined as fatal coronary heart disease
(based on International Classification of Diseases
codes), non-fatal myocardial infarction (using WHO
criteria), or coronary stenosis (>50% narrowing of
one of more coronary arteries assessed by angiogra-
phy).Allstudyparticipantsprovidedwritteninformed
consent for use of their DNA for genetic testing.
Statistical analyses
Appendix5onbmj.comprovidesdetailsofthestatistical
methods. Levels of C reactive protein and other posi-
tively skewed variables were natural log transformed.
Principal analyses assumed additive effects (per allele
associations), with subsidiary analyses of other genetic
models. All analyses of circulating C reactive protein
and other risk factors susceptible to reverse association
biaseswerelimitedtoparticipantswithoutknowncoron-
ary heart disease at time of blood sampling. We calcu-
lated study specific associations of baseline (and repeat)
values of C reactive protein concentration and other
characteristics with a linear regression model, adjusted
for sex and ethnicity and combined across studies using
rs3093077
rs1205
rs1130864
rs1800947
0.21 (0.17 to 0.24)
0.18 (0.16 to 0.20)
0.13 (0.12 to 0.15)
0.26 (0.23 to 0.29)
0.06
0.67
0.30
0.94
-0.1 0 0.1 0.2 0.3 0.4 0.85 0.90 0.95 1 1.05 1.10
Single nucleotide
polymorphism
Per allele higher
mean ln CRP
(95% CI), mg/L
Per allele higher
mean ln CRP
(95% CI), mg/L
Per allele risk
ratio for CHD
(95% CI)
Per allele risk
ratio for CHD
(95% CI)
0.93 (0.87 to 1.00)
1.00 (0.98 to 1.02)
0.98 (0.96 to 1.00)
0.99 (0.94 to 1.03)
Allele
frequency*
19/15 133/96 807
43/40 527/172 567
41/37 145/157 905
31/31 636/93 507
No of studies/cases
/participants†
Fig 2 | Estimates of association of each single nucleotide polymorphism with ln concentrations of C reactive protein and risk of
coronary heart disease (CHD). *Frequency of allele for increased concentrations of circulating ln C reactive protein (that is, risk
allele). Associations presented per additional copy of risk allele. †For associations between single nucleotide polymorphism
and coronary heart disease, studies with <10 cases or <50 participants were excluded from analyses. Study specific estimates
stratified, where appropriate, by sex, ethnicity, and trial arm and combined with random effects models. Maximum available
data on genetic variants, circulating C reactive protein, and coronary heart disease used for analyses; sensitivity analyses
restricted to participants with data on C reactive protein single nucleotide polymorphisms, circulating C reactive protein, and
coronary heart disease did not differ from current analyses. Fig C in appendix 3 on bmj.com shows study specific associations
between single nucleotide polymorphism and C reactive protein and coronary heart disease for each single nucleotide
polymorphism
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mates ofsingle nucleotide polymorphism andCreactive
protein correlates.
21 We calculated risk ratios for coron-
ary heart disease per addition of a prespecified risk allele
of each single nucleotide polymorphism using a two
stageapproach,stratified,whereappropriate,bysex,eth-
nicity, and adjustment for age. We calculated natural log
(ln) risk ratios separately within each study before pool-
ingthemacrossstudiesbyrandomeffectsmeta-analysis.
3
For prospective cohort studies, we used stratified Cox
proportional hazard regression models to calculate
hazard ratios for incident coronary heart disease risk.
For retrospective studies (and for prevalent coronary
heartdiseasecasesinprospectivestudies),weusedeither
conditionalorunconditionallogisticregressionasappro-
priate to calculate odds ratios. Hazard ratios and odds
ratios were assumed to approximate the same risk ratios.
To correct risk ratios for coronary heart disease for
potentialbias causedby measurement errorand varia-
bility in risk factors within an individual (“regression
dilutionbias”), we madeallowance forregressiondilu-
tion bias in both C reactive protein concentration and
potential confounding factors. Regression dilution
ratios were obtained by regressing 93998 serial mea-
surements (mean interval 2.9 (SD 1.9) years) from
35023 participants on baseline levels of the relevant
characteristic, adjusted for conventional risk factors
plus baseline ln C reactive protein concentration and
duration of follow-up.
22 Risk ratios for coronary heart
disease, adjusted for conventional risk factors, were
calculated per 1 SD higher usual ln concentration in
participants. This difference corresponds to an
approximately threefold difference on the original
scaleofCreactiveproteinmeasurement,asthepooled
standard deviation for baseline ln C reactive protein is
1.05 (that is, e
1.05). To estimate the effect of genetically
predictedCreactiveproteinoncoronaryheartdisease,
we used a hierarchical Bayesian meta-analysis
framework.
23 Using information on baseline ln C
reactive protein concentration within each genotype
or haplotype group, we obtained a summary estimate
from meta-analysis of study specific risk ratios for cor-
onary heart disease per 1 SD higher genetically pre-
dicted C reactive protein concentration. We used I
2
statistic to assess heterogeneity.
24 Diversity at the
study level was investigated by grouping studies by
relevant characteristics and by meta-regression. Effect
modification by several prespecified variables was
investigated by formal tests of interaction. Conven-
tional analyses were conducted in Stata v 11.0 and
Bayesian analyses in WinBUGS.
RESULTS
Mean age at entry was 59 years (SD 10), 89% of parti-
cipants were of European descent, and 44% were
women. Minor allele frequencies ranged from 0.06 to
0.33 for the principal single nucleotide poly-
morphisms.Foranygivenpolymorphism,minorallele
frequencies were similar across studies.Mean baseline
concentrations of C reactive protein varied across stu-
dies, though standard deviations were broadly similar
(see fig B in appendix 3 on bmj.com), with an overall
median of 1.7 (5th, 95th centile 0.3, 12.7) mg/L. The
regression dilution ratio of ln C reactive protein,
adjusted for age and sex, was 0.57 (95% confidence
interval 0.51 to 0.64), similar to those observed here
for systolic blood pressure (0.51, 0.48 to 0.54), and
total cholesterol (0.55, 0.52 to 0.60).
CRP variants, C reactive protein concentration, and levels
of other risk factors
Each of these CRP variants was associated with base-
line C reactive protein, with per allele differences in C
reactiveproteinconcentrationof23%(95%confidence
interval19%to27%)forrs3093077,19%(17%to21%)
for rs1205, 14% (12% to 16%) for rs1130864, and 30%
(26% to 34%) for rs1800947 (P<0.001; fig 1) (see also
fig C in appendix 3 and table F in appendix 1 on
bmj.com). These associations were consistent over
(1) T/C/T/G
(2) T/C/C/G
(3) G/C/C/G
(4) T/T/C/G
(5) T/T/C/C
Reference
-0.10 (-0.12 to -0.08)
0.10 (0.07 to 0.13)
-0.21 (-0.24 to 0.17)
-0.34 (-0.39 to -0.30)
0.30
0.24
0.05
0.13
0.03
-0.3 -0.2 -0.4 -0.1 0 0.1 0.2 0.90 0.95 1.05 11 . 1 0
Haplotype
(rs3093077/
rs1205/
rs1130864/
rs1800947)
Change in mean ln
CRP per copy of
haplotype versus
reference haplotype 1
(95% CI), mg/L
Change in mean ln
CRP per copy of
haplotype versus
reference haplotype 1
(95% CI), mg/L
Reference
1.01 (0.97 to 1.04)
0.98 (0.92 to 1.03)
0.99 (0.96 to 1.03)
0.98 (0.91 to 1.05)
Risk ratio (95% CI)
for CHD per copy of
haplotype versus
reference haplotype 1
Risk ratio (95% CI)
for CHD per copy of
haplotype versus
reference haplotype 1
Frequency*
Fig 3 | Estimates of association of each haplotype with ln concentrations of CRP and risk of coronary heart disease. *Based on
seven haplotypes and therefore do not add up to 1. Haplotypes 6 and 7 excluded because they represent individuals for whom
it was not possible to assign to primary haplotypes because of missing data in rs3093077 and rs1800947. See table A in
appendix 1, fig F in appendix 3, and appendix 5 for details of these haplotypes and explanation of methods. Additive
haplotype model was used to estimate effect of each haplotype relative to two copies of haplotype 1. See appendix 5 for
details of this model. Data limited to populations of European descent, for which it was possible to assign haplotypes based
on linkage disequilibrium information between single nucleotide polymorphisms (see appendix 5). Studies with <10 cases or
<50 participants excluded. Study specific estimates were stratified, where appropriate, by sex, ethnicity, and trial arm and
combined with multivariate random effects meta-analysis. Data available on up to 25960 cases and up to 139251
participants of European descent from 33 studies. Fig G in appendix 3 shows study specific associations between haplotype
and C reactive protein and coronary heart disease for each haplotype
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tein taken several years apart (see fig D in appendix 3
on bmj.com). With the exception of ethnicity (with
which the principal variants were strongly correlated;
P<0.001), single genetic variants associated with C
reactiveproteinwerenotassociatedwithconventional
riskfactorsorotherinflammatorymarkers(fig1).With
haplotype 1 as a reference, CRP haplotypes were asso-
ciatedwithdifferencesinlnCreactiveproteinconcen-
tration ranging from 0.1 to 0.34 mg/L and were not
associated with conventional risk factors and other
characteristics (see figs E-G in appendix 3 and table F
in appendix 1 on bmj.com). By contrast, baseline C
reactive protein concentration itself was associated
with conventional risk factors, inflammatory markers,
and other characteristics (see table G in appendix 1 on
bmj.com).
Risk ratios for coronary heart disease with CRP genetic
variants
Risk ratios for coronary heart disease per addition of a
risk(“Creactiveproteinraising”)allelewere0.93(0.87to
1.00) for rs3093077, 1.00 (0.98 to 1.02) for rs1205, 0.98
(0.96 to 1.00) for rs1130864, and 0.99 (0.94 to 1.03) for
rs1800947 (fig 2). There was modest heterogeneity in
these estimates (I
2 values for those risk ratios were 0%,
26%,0%,and0%,respectively,seefigCinappendix3on
bmj.com) with similar findings under a range of circum-
stances(seetableHinappendix1onbmj.com).Forhap-
lotype analyses, risk ratios for coronary heart disease per
copy of haplotype (relative to two copies of haplotype 1)
were 1.01 (0.97 to 1.04) with haplotype 2, 0.98 (0.92 to
1.03)withhaplotype3,0.99(0.96to1.03)withhaplotype
4,and0.98(0.91to1.05)withhaplotype5(fig3)(seealso
fig F in appendix 3 on bmj.com). There was little hetero-
geneity in these risk ratios (see fig G in appendix 3 on
bmj.com). Data were insufficient to investigate effects in
different ethnic groups.
Risk ratios for coronary heart disease with usual
concentrations of C reactive protein
In analyses restricted to 27 long term prospective stu-
dies comprising 124931 participants and 10981 inci-
dent cases of coronary heart disease, there was an
approximately log linear association between C reac-
tive protein concentration and risk of coronary heart
disease (see fig H in appendix 3 on bmj.com). In these
studies, the risk ratio for coronary heart disease,
adjusted for age, sex, and ethnicity only, was 1.49
(1.40 to 1.59) per 1 SD higher “usual” ln C reactive
protein concentration (that is, a risk ratio that has
made allowance for regression dilution) (fig 4). The
risk ratio for coronary heart disease was 1.33 (1.23 to
1.43) after further adjustment for smoking status, his-
tory of diabetes mellitus, and usual levels of systolic
bloodpressure,bodymassindex(BMI),non-highden-
sity lipoprotein cholesterol, high density lipoprotein
cholesterol, and triglyceride concentrations. There
was little evidence of heterogeneity (see fig I in appen-
dix 3 on bmj.com). Risk ratios with higher C reactive
protein concentration were broadly similar under a
range of circumstances (see fig J in appendix 3 on
bmj.com).Multivariable adjustedriskratios forcoron-
aryheartdiseasewithCreactiveproteinconcentration
weakened after further adjustment for fibrinogen or
interleukin 6 (see table I in appendix 1 on bmj.com).
Integration of data on CRP variants and C reactive protein
concentration
Riskratiosforcoronaryheartdiseasewere1.00(0.90to
1.13)per1SDhighergeneticallyraisedCreactivepro-
tein as determined by all four principal single nucleo-
tide polymorphisms (163174 participants, 37736
cases, 44 studies). This corresponds to a risk ratio of
1.00 (0.97 to 1.02) per 20% lower C reactive protein,
which is equivalent to about 0.38 mg/L lower C reac-
tive protein when the population mean is 1.88 mg/L.
From information on all common CRP haplotypes in
populations of European descent, the risk ratio was
1.00 (0.89 to 1.12; 152678 participants, 33589 cases,
39 studies; fig 4) (see also fig K in appendix 3 on
bmj.com).
We observed qualitatively similar results to those
reported above in analyses that used different genetic
models(seefigLinappendix3onbmj.com);excluded
variantsorstudiesthatdeviatedfromHardy-Weinberg
equilibrium or were judged to be insufficiently strong
genetic instruments
25; used fixed effect meta-analysis
models (see figs C, G, I, and K in appendix 3 on
bmj.com); omitted the 11734 participants who
reportedusing cardiovascular drugs(including statins)
at baseline; omitted the 18198 participants in clinical
trials; included only people of European descent (see
fig M in appendix 3 on bmj.com); compared prospec-
tive and retrospective studies (fig K in appendix 3 on
bmj.com); and compared larger studies versus smaller
studies (available on request).
DISCUSSION
Implications for disease aetiology
Usingtheprincipleofmendelianrandomisation,weused
CRP genetic variants as proxies to help judge whether
usual C reactive protein concentration is causally rele-
vant to coronary heart disease. Our results indicate that
genetically raised concentrations of C reactive protein
are unrelated to conventional risk factors and risk of cor-
onary heart disease. Given the power of our study, these
results suggest that C reactive protein concentration is
Circulating usual concentrations of CRP
  Adjusted for age, sex, and ethnicity
  Further adjusted†
Genetically raised concentrations of CRP‡
  SNP analyses
  Haplotype analyses
1.49 (1.40 to 1.59)
1.33 (1.23 to 1.43)
1.00 (0.90 to 1.13)
1.00 (0.89 to 1.12)
1 1.2 0.8 1.4 1.6 1.8
Risk ratio* (95% CI)
for CHD per 1 SD
higher ln CRP (mg/L)
Risk ratio* (95% CI)
for CHD per 1 SD
higher ln CRP (mg/L)
Fig 4 |Estimates of association of circulating concentrations and genetically raised
concentrations of C reactive protein (CRP) with risk of coronary heart disease (CHD). *Corrected
for regression dilution in C reactive protein and potential confounding factors.
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heart disease. Furthermore, we found no material asso-
ciations between CRP genetic variants and fibrinogen,
interleukin 6, and leucocyte count. Because these results
suggest that C reactive protein concentration is unlikely
to be causally relevant to these inflammatory markers,
thefindingsimplythatanalysesofCreactiveproteincon-
centration and disease outcomes should adjust for these
inflammatorymarkers(thatis,treatthemasgenuinecon-
founders). Indeed, risk ratios for coronary heart disease
with circulating C reactive protein were further wea-
kenedwhenweadjustedforsuchinflammatorymarkers.
This finding further decreases the likelihood that C reac-
tive protein concentration is causally relevant.
3 Collec-
tively, therefore, our results suggest that studies seeking
totesttheinflammationhypothesisincoronaryheartdis-
easeshouldexamineinflammatorymediatorsotherthan
C reactive protein.
12627
Study strengths
Our analysis builds on previous studies, combining
several major advantages.
12-18 Firstly, we carefully
selected and assessed specific polymorphisms to cap-
ture the full range of common variability in the CRP
gene. Variants in the CRP gene related to C reactive
proteinconcentrationaremorelikelytobeexclusively
associated with C reactive protein concentration than
variantsinothergenes.
18Secondly,ourstudyinvolved
over90000moreparticipantsthanthepreviouslargest
study, substantially enhancing statistical power.
Thirdly, the availability of data from individual parti-
cipantsenabledacomprehensiveanddetailedrangeof
analyses not possible with aggregated data (such as
haplotype analyses and instrumental variables
analyses
23). For example, compared with analysis of
single nucleotide polymorphisms, haplotype analysis
allows more complete consideration of genetic varia-
tionatalocus.Fourthly,wehadinformationon94000
serial measurements, enabling correction of risk ratios
for regression dilution bias
22 and yielding results sup-
porting the idea that CRP variants are related to life-
time variation in C reactive protein concentration.
Finally, the generalisability of our results is supported
by their consistency in 47 studies in 15 countries.
24
Potential limitations
For studies that did not directly measure the principal
CRP single nucleotide polymorphisms we investi-
gated, we used alternative variants as proxies. There
is the possibility of residual confounding by unrecog-
nised effects of genotypes on other risk factors and by
adaptation during early life to compensate for geneti-
cally raised concentrations of C reactive protein,
8
though there is no evidence of their impact in the cur-
rentcontext.Furtherstudyisneededinnon-whitepeo-
ple, particularly as the genetic architecture of CRP
differs by ethnicity.
28
Broader context
Our results generally agree with those from previous
studies that used other methods, such as the null find-
ings of in vivo studies of atherosclerosis that have
involvedeitherinjectionofCreactiveproteinindiffer-
ent species or transgenic expression of C reactive pro-
teininmiceandrabbits.
2930Ourresultsalsoagreewith
well designed in vitro studies, in which uncontami-
nated preparations of C reactive protein were used,
which have generally failed to produce persuasive evi-
dence for pro-atherothrombotic effects of C reactive
protein on various cell types.
3132 Irrespective of the
causalrelevanceofCreactiveproteinitselftocoronary
heart disease, however, there is considerable evidence
that persistent inflammation might contribute to cor-
onary heart disease.
133Hence, there is a need to iden-
tify specific genetic, biochemical, and environmental
determinants responsible for these associations. Anti-
inflammatory interventions have not yet been ade-
quately studied to test the inflammation hypothesis in
coronary heart disease.
12627
Furthermore, as distinct from possible associations
of underlying usual C reactive protein concentration
with later development of coronary heart disease,
there is interest in the possibility that massively raised
concentrationsofCreactiveproteinatthetimeofacute
ischaemic events could contribute to severity and out-
come of ischaemic lesions.
34 Our findings also do not
addressthe separateissueofthe valueofmeasurement
of circulating C reactive protein in prediction of long
term vascular risk.
35
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WHAT IS ALREADY KNOWN ON THIS TOPIC
Blood concentrations of C reactive protein are strongly and continuously associated with
future risk of coronary heart disease, though it is unknown whether this correlation reflects
cause and effect
Genetic variants related to C reactive protein can be used as proxies for C reactive protein
concentration to help judge causality (“mendelian randomisation analyses”)
Previous studies have been insufficiently powerful and detailed to evaluate the possibility of
any moderate causal role for C reactive protein in coronary heart disease
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